Doug Drysdale, Founder and CEO“What's still worth paying for is judgment about what to do, and hands to do it,” says Doug Drysdale, founder and CEO.
Katogen combines that experience with AI-enabled intelligence through a small team of operators who have been there before. The team applies that intelligence to strategy while staying involved through execution and challenging the assumptions behind a decision.
Building Decisions around Experience
Drysdale has spent 35 years in biopharma, including two decades as CEO of four companies, from startups to turnarounds. He has closed 17 acquisitions and raised more than USD 4 billion. That experience shapes Katogen’s advice on capital allocation. It asks what each development dollar will produce in evidence and whether that evidence will change what an investor or acquirer will pay.
For first-time founders and scientific inventors, the gap can be significant. They may understand their science but have less experience with financing, scaling and execution. One pre-IND engagement shows how that perspective can change the question. Several companies with similar technology were pursuing the same indication, but none were getting funded. Katogen helped the client change its target indication and positioning, a shift followed by significant nine-figure funding.
That same judgment applies to sequencing. The science can be sound, yet a company can still fail because it ran a trial it could not fund through to readout. Katogen focuses on the runway and whether a company can reach the next value inflection without a dilutive raise at the wrong price. A founder asked Katogen to help build the case for a Phase 2 study with 11 months of cash available. Rather than move straight to the study, Katogen helped prioritize financing before launching it.
-
What's still worth paying for is judgment about what to do, and hands to do it.
Three intelligence tools support that work. Radar tracks 420 US-listed drug developers, highlighting catalysts, ownership and developments across indications, funding and competitor trials. Sentinel provides daily alerts on selected companies, while Engine enables deeper analysis of a company, asset or disease area, using 101 official primary data sources and hundreds of millions of documents to produce a board-ready decision document in minutes.
For Katogen, intelligence tells you what's happening. Strategy turns that into a decision, and Operations puts people on it. The three functions stay together so those responsible for execution are involved in developing the strategy and understand its assumptions.
A delivery platform illustrates that connection. Its API development work was solid, but sterile fill capacity was not available at a price the company could afford. The constraint changed the recommendation from build to rent.
Keeping Strategy Close to Execution
Katogen's small team functions as a “biotech team in a box,” giving small, founder-led companies experienced specialists without building those capabilities in-house. That bench can step into work such as RFPs, CRO and CDMO selection, vendor management and project management. For one client, Katogen immediately put someone on the work to qualify a second supplier ahead of a filing. As Drysdale explains, “That isn't a strategy problem. It's twelve weeks of hands-on work, and we put somebody on it immediately.”
An API company needed greater scale, but rather than build that capacity itself, Katogen drove a merger with a company that already had it, avoiding CapEx, saving time and reducing execution risk.
For Katogen, sequencing remains a recurring consideration in biopharma decision-making. As Katogen grows, Drysdale plans to expand its experienced bench across fractional leadership, CEO mentoring and board support, bringing the experience gained across multiple companies into new engagements. Together, these capabilities explain Katogen's recognition as the Top Biopharma Intelligence and Strategy Consulting Services 2026.
What Biopharma Leaders Need from Strategy Consultants
Growth-stage biopharma companies have access to more market and scientific information than ever, but the real challenge is connecting the signals before committing capital. A development plan may look promising on its own, even as investor appetite, competing programs, patent activity or regulatory changes suggest otherwise. The value of a consulting partner lies not in the volume of analysis it delivers, but in how effectively it turns primary-source intelligence into decisions about development priorities and capital allocation.
Reliable intelligence starts with the quality of the sources behind it. Search tools and general-purpose AI can make research faster, but they cannot replace the work of checking where evidence comes from and understanding how one development affects another. Buyers should look for providers that use primary records and bring together information from company filings, regulatory sources, clinical activity and intellectual property. The real value lies in connecting these pieces to see the bigger picture, not in collecting more documents.
Experience at the decision table matters just as much. Growth-stage companies often have scientific leadership that knows the asset deeply but has less experience with financing, scaling, company building and board-level tradeoffs. Advice becomes more useful when the people shaping strategy have lived through those decisions and can challenge the original framing of a problem. A provider should be able to test whether the requested path is actually the best path, rather than simply producing analysis around the brief it was given. Senior involvement also affects how quickly a recommendation can be translated into action when circumstances change.
“Katogen also provides experienced fractional support for vendor selection and project management, with additional help around financing and communications when needed.”
How a consulting engagement is structured can reveal whether senior expertise is hands-on or simply part of the pitch. Buyers should ask who will actually do the work, how closely they can work with experienced operators and whether those experts stay involved when recommendations meet real-world constraints such as vendors, timelines, budgets and board expectations. Ultimately, direct access to experienced people who take responsibility for the work can matter more than the size of the consulting team.
Execution matters just as much as strategy. Early-stage biopharma companies often keep their teams small and rely on outside partners to fill the gaps. But a good plan can lose momentum if a consulting firm steps away before implementation begins. Buyers should look for partners who can help put plans into action, manage projects and bring in experienced fractional talent when needed. That support may also extend to financing and communications as the company advances. The goal is not to build a management team out of consultants, but to give a lean team the expertise it needs, when it needs it.
Katogen combines AI-supported intelligence with senior operators who can move from analysis into execution for growth-stage biopharma companies. Its platform draws from 101 primary sources and hundreds of millions of primary documents, giving strategy work a broad evidence base rather than a narrow market snapshot. Katogen also provides experienced fractional support for vendor selection and project management, with additional help around financing and communications when needed. Its senior team can also provide CEO mentoring and board support when founders need experienced guidance around company-building decisions. That model gives founders access to business experience without requiring a full internal team. For buyers that need both intelligence and hands-on execution, Katogen merits consideration as a biopharma strategy consulting partner.
...Read more
